Over the past several years, there has been a multitude of media and lawsuits challenging the trustworthiness of this system—and no participant in the system has been spared. But the pharmaceutical industry has come under the most scrutiny and has, I believe, suffered the biggest loss of public trust. The consequences of this are profoundly disturbing and could potentially undermine industry's ability to continue to invent, develop, manufacture, and distribute new medicines.
Industry, critics, doctors, and regulators agree that the ideal world would be one in which industry produces a constant stream of highly innovative medicines that are perfectly safe and accessible to all. Most of us recognize the reality that we (society) must constantly trade off one against the other. Critics challenge our values in making these trade-offs. Although I believe in the fundamental value and integrity of the system that produces miraculous drugs such as "Sutent," "Chantix," and "Maraviroc," I think we, as an industry, need to do a better job of allowing people to see into the discovery and development process so they can understand for themselves the quality and integrity that underlies our own confidence in the system.
What does transparency look like?
The leadership at Pfizer (and many other companies) recognizes that consumers need to know more about what we do and has dramatically increased its transparency. Take a look:
2002: Pfizer discloses all political contributions and begins posting clinical trials online at http://www.clinicaltrials.gov/
2004: Pfizer begins posting clinical study results online at http://www.clinicalstudyresults.org/
2006: Pfizer begins posting on its website all compounds in its research and development pipeline
2007: Pfizer begins posting on its website all FDA postmarketing commitments
2008: Pfizer begins posting on its website contributions of $500 or greater to US patient, scientific, and medical organizations.
Benefits and risks
Increased transparency provides patients with information about clinical trials that they might be interested in participating in, researchers with information about what work is being done and where, doctors with up-to-date information on the status of particular drugs, and regulators the ability to compare development programs across therapeutic areas and companies. As an ongoing record, it provides accountability and a comprehensive record of what research has been done —whether successful or not.
Of course, while the benefits of disclosure are real, there are risks as well. Will patients really be able to interpret results? Will physicians? Will plaintiffs' attorneys use these new data to file frivolous lawsuits, needlessly driving up development costs?
As more information becomes available, researchers of differing quality will attempt to analyze it and will publish these analyses. Many of these papers will be high quality efforts by seasoned experts. Some will not. But the public's and media's capacity to distinguish between the two is limited. And there is the rub. By exposing the underlying processes to public scrutiny, we hope to build confidence and trust—but if this information is used improperly, we could further undermine public confidence in this work.